Please login to the form below

Not currently logged in

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

edit-Kantar_Media_PHPharma companies spent more than $342m on print advertising in professional health journals in the first six months of this year, according to new figures.

Kantar Media says its research shows a 1% rise in pharma's print journal advertising and it names Johnson & Johnson - whose spending of almost $23m on advertising drugs products accounts for 7$ of the total advertising share - as the industry's single biggest spender.

GlaxoSmithKline was the second highest spender investing $9m, less than half that spent by Johnson & Johnson, but up 110% for the company compared to the 2013 period.

Takeda, Pfizer and Novartis were the next highest spenders, each investing $7m in print advertising.

Kantar says the total number of advertising pages purchased in medical journals was down, year-on-year, by 2% to 53,094.

On a therapy basis, oncology brands lead the spending, accounting for $25m and making up 7% of the total market share, followed by oral diabetes drugs ($14m), up 52% from July 2013, and forming 4% of sales.

Meanwhile, in brand terms Invokana, the first-in-class type 2 diabetes drug from J&J's Janssen unit was the most advertised drug product in the first six months of 2014.

J&J spent $12m to advertise the drug, which was approved in the US in April 2013, was up 84% on the same period in 2013, while Lundbeck's antidepressant Brintellix was next in spending terms with $7m.

Behind those two came Bayer's blood clot drug Xarelto and Forest's anti-depression treatment Fetzima, each of which spent $5m on print journal advertising.

Article by
Kirstie Pickering

11th September 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...